LSD molecule:

Image from PubChem

LSD Clinical Trials

A Single Center, Randomized, Double-blind, Double-dummy, Placebo- and Active-controlled, Six-way Crossover Single-dose Study to Evaluate the Relative Abuse Potential of Almorexant in Recreational Central Nervous System (CNS) Depressant Drug Users

To see complete record on, please visit this link

Id: NCT01987739

Organisation Name: Midnight Pharma, LLC

Overal Status: Completed

Start Date: September 2009

Last Update: February 12, 2016

Lead Sponsor: Midnight Pharma, LLC

Brief Summary: This was a six-way crossover study with six single-dose treatment sessions. The profile of acute effects on abuse potential measures of different almorexant doses was compared to that of placebo and two doses of zolpidem

  • Abuse Potential Study

Total execution time in seconds: 0.97208309173584